Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

177Lu-PSMA-617

- PMLiVE

Novartis and Google to fund ‘robotic pill’ maker

Firms sign up to Rani Therapeutics’ new drug delivery system

- PMLiVE

Afinitor set for filing this year in neuroendocrine cancer

Novartis drug is already approved for breast and renal cancers

Infographic: Prostate Cancer Market Snapshot

An overview of the prostate cancer patientDownload our Therapy Watch PCa market snapshot which provides you with an overview of the prostate cancer patient and the therapy regimens followed by...

Research Partnership

- PMLiVE

Pfizer maintains lead in top CNS drug sales – just

But Biogen is looking to take the top spot next year as its MS portfolio grows

- PMLiVE

Novartis biosimilar blocked by US court

Swiss firm’s Neupogen copy has its injunction upheld at appeal

- PMLiVE

EMA clears Novartis’ lung cancer drug Zykadia

First treatment option in Europe for patients with ALK-postitive NSCLC

- PMLiVE

Heart drug sales continue downward spiral

But revenue has stabilised after a tough three years of patent expiries

- PMLiVE

Prostate cancer treatment market to treble to £8.2bn by 2023

But GlobalData predict growth could be hampered by patent loss for Zytiga

- PMLiVE

Pfizer falls as strong dollar and generic erosion bites

First quarter results beat analysts’ estimates but sales still sliding

- PMLiVE

Novartis still hungry after absorbing GSK oncology

CEO says firm is looking to strengthen pipelines in its three businesses

- PMLiVE

Pfizer breast cancer drug shines in latest trial

Study with Ibrance stopped early because of its success

- PMLiVE

Novartis knocks Pfizer off sales leader board

Swiss firm takes US giant’s crown as diversification programme and pipeline come to fruition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links